

KU LEUVEN

LEUVEN UNIVERSITY
VACCINOLOGY CENTRE


Immunogenicity and safety of the nine-valent HPV vaccine in people living with HIV (PLWH) and solid organ transplant recipients

BREACH symposium
30 November 2021

Lise Boey, Ans Curinckx, Mathieu Roelants, Inge Derdelinckx, Eric Van Wijngaerden, Paul De Munter, Robin Vos, Dirk Kuypers, Johan Van Cleemput, Corinne Vandermeulen

 @BoeyLise

 lise.boey@kuleuven.be




Partner:



Importance of HPV vaccination for PLWH and transplant recipients

→ Higher incidence of persistent HPV infection


→ Higher incidence of anogenital warts and dysplastic and cancer lesions




HPV vaccination in PLWH and transplant recipients

What was known?


- Sparse data for bivalent HPV and qHPV vaccine, especially for SOT recipients
 - Suboptimal immunogenicity in SOT recipients and PLWH with low CD4-counts
- No data for 9vHPV vaccine




Immune response and safety in 100 HIV patients and 171 transplant patients



Immune response: Seroconversion (95%CI)



GMTs following vaccination (95%CI)





Safety

Injection-site adverse event

Pain (60%)

Swelling (8%)

Redness (7%)

Systemic AE


Headache (9%)

Conclusion

Immunogenicity of the 9vHPV vaccine **is excellent in PLWH with high CD4-counts** but **suboptimal in solid organ transplant patients** due to immunosuppressive medication.

9vHPV vaccine is safe and well tolerated in both groups

(detailed analysis and discussion: Boey et al. Clin Infect Dis 2020.
<https://doi.org/10.1093/cid/ciaa1897>.)



**Thank you for your
attention.**

**Are there any
questions?**